TG Therapeutics Q2 revenue soars, helped by BRIUMVI sales

TG Therapeutics

04/08/2025 12:13

Overview

TG Therapeutics Q2 2025 rev rises 91% yr/yr, driven by BRIUMVI sales

Co raises 2025 BRIUMVI U.S. net revenue target to $570-$575 mln

BRIUMVI approved in EU, UK, Switzerland, and Australia

Outlook

TG Therapeutics raises full-year 2025 BRIUMVI U.S. revenue target to $570-$575 mln

Company increases 2025 global revenue target to approximately $585 mln

TG Therapeutics cites strong uptake and physician confidence in BRIUMVI

Company sees BRIUMVI well positioned to redefine multiple sclerosis treatment expectations

Result Drivers

BRIUMVI UPTAKE - Strong uptake and increasing physician confidence in BRIUMVI driving revenue growth, per CEO Michael S. Weiss

LICENSE REVENUE - License, milestone, royalty and other revenue rose to $2.3 million from approximately $0.9 million

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Product Revenue
$138.84 mln
Q2 Net Income
$28.19 mln
Q2 Operating Income
$34.84 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for TG Therapeutics Inc is $46.00, about 23.9% above its August 1 closing price of $35.02

The stock recently traded at 27 times the next 12-month earnings vs. a P/E of 36 three months ago

Press Release: ID:nGNX80h1Tx

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)